Posts tagged Pharmiweb.com
ViroCell strengthens senior management team with appointment of Nick Maishman as COO
ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

Read More
In the NewsFlorence Buchananviral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmiweb.com, UK CDMO, ViroCell, John W. Hadden II, Farzin Farzaneh, Matthew Shaw, Scientific Advisory Board
ViroCell Announces new Board appointments
ViroCell Announces new Board appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

Read More
In the NewsFlorence BuchananCDMO, ViroCell Board of Directors, Pharmiweb.com, UK CDMO, ViroCell, Recro Pharma, Board of Directors, Scientific Advisory Board, Dr. Martin Pule, J. David Enloe, John W. Hadden II, Farzin Farzaneh, gene therapy, cell therapy, CGT, viral vector, AAV vectors, lentivirus vectors, University College London